EA201792226A1 - Полипептиды, содержащие de novo связывающий домен, и их применение - Google Patents
Полипептиды, содержащие de novo связывающий домен, и их применениеInfo
- Publication number
- EA201792226A1 EA201792226A1 EA201792226A EA201792226A EA201792226A1 EA 201792226 A1 EA201792226 A1 EA 201792226A1 EA 201792226 A EA201792226 A EA 201792226A EA 201792226 A EA201792226 A EA 201792226A EA 201792226 A1 EA201792226 A1 EA 201792226A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- dbdpp
- binding domain
- libraries
- polypeptides containing
- application
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 238000012216 screening Methods 0.000 abstract 2
- 238000001261 affinity purification Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001104—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/00111—Hepatocyte growth factor receptor [HGFR or c-met]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001112—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001111—Immunoglobulin superfamily
- A61K39/001113—CD22, BL-CAM, siglec-2 or sialic acid- binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001124—CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
- A61K39/001195—Prostate specific membrane antigen [PSMA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464413—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Abstract
В настоящей заявке предложены полипептиды, содержащие de novo связывающий домен (DBDpp), которые специфично связывают представляющую интерес мишень. Также предложены нуклеиновые кислоты, кодирующие DBDpp, векторы и клетки-хозяева, содержащие нуклеиновые кислоты. Также включены библиотеки DBDpp, способы получения и скрининга таких библиотек и DBDpp, идентифицированные в таких библиотеках и скринингах. Дополнительно предложены способы получения и применения DBDpp. Такое применение включает, без ограничения, аффинную очистку и диагностические и терапевтические применения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562143772P | 2015-04-06 | 2015-04-06 | |
PCT/US2016/025868 WO2016164305A1 (en) | 2015-04-06 | 2016-04-04 | De novo binding domain containing polypeptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201792226A1 true EA201792226A1 (ru) | 2018-08-31 |
Family
ID=57072017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201792226A EA201792226A1 (ru) | 2015-04-06 | 2016-04-04 | Полипептиды, содержащие de novo связывающий домен, и их применение |
Country Status (27)
Country | Link |
---|---|
US (8) | US10647775B2 (ru) |
EP (3) | EP3903804A1 (ru) |
JP (4) | JP6871232B2 (ru) |
KR (1) | KR20180012747A (ru) |
CN (3) | CN107921090A (ru) |
AU (3) | AU2016246426B2 (ru) |
BR (1) | BR112017021308A2 (ru) |
CA (2) | CA2981711A1 (ru) |
CY (1) | CY1124453T1 (ru) |
DK (2) | DK3280433T3 (ru) |
EA (1) | EA201792226A1 (ru) |
ES (2) | ES2866202T3 (ru) |
HK (2) | HK1249421A1 (ru) |
HR (1) | HRP20210498T1 (ru) |
HU (1) | HUE054435T2 (ru) |
IL (2) | IL254907B (ru) |
LT (1) | LT3280432T (ru) |
MX (2) | MX2017012679A (ru) |
NZ (1) | NZ736022A (ru) |
PH (1) | PH12017501834A1 (ru) |
PL (1) | PL3280432T3 (ru) |
PT (1) | PT3280432T (ru) |
RS (1) | RS61907B1 (ru) |
SG (2) | SG10202007987QA (ru) |
SI (1) | SI3280432T1 (ru) |
WO (3) | WO2016164305A1 (ru) |
ZA (1) | ZA201706875B (ru) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2017012679A (es) * | 2015-04-06 | 2018-02-09 | Subdomain Llc | Polipeptidos que contienen dominios de union de novo y usos de los mismos. |
WO2018075586A1 (en) * | 2016-10-18 | 2018-04-26 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof |
EP3579848A4 (en) | 2017-02-08 | 2021-03-03 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR ACTIVATING NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES FOR TREATING CANCER |
BR112019016553A2 (pt) * | 2017-02-10 | 2020-03-31 | Dragonfly Therapeutics, Inc. | Proteínas que se ligam ao psma, nkg2d e cd16 |
JP7257323B2 (ja) * | 2017-02-10 | 2023-04-13 | ドラゴンフライ セラピューティクス, インコーポレイテッド | Bcma、nkg2d及びcd16と結合するタンパク質 |
AU2018220736A1 (en) | 2017-02-20 | 2019-09-05 | Dragonfly Therapeutics, Inc. | Proteins binding HER2, NKG2D and CD16 |
JP7161940B2 (ja) * | 2017-05-10 | 2022-10-27 | ウェルスタット イミューノ セラピューティクス, エルエルシー | がんの治療のための、補体不活性化に耐性のエンベロープウイルス |
CN107216395B (zh) * | 2017-07-03 | 2018-07-20 | 上海科医联创生物科技有限公司 | 一种tm4sf1特异性嵌合抗原受体及其应用 |
CN111372590A (zh) * | 2017-09-23 | 2020-07-03 | 纪念斯隆-凯特林癌症中心 | A33抗体组合物及在放射免疫疗法中使用其的方法 |
TWI701259B (zh) * | 2017-11-09 | 2020-08-11 | 大陸商上海懷越生物科技有限公司 | 4﹘1bb抗體及其製備方法和應用 |
WO2019099440A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Multifunctional immune cell therapies |
JP7285267B2 (ja) * | 2017-11-14 | 2023-06-01 | アーセルクス インコーポレイテッド | Dドメイン含有ポリペプチドおよびその使用 |
US11464803B2 (en) | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
CN112368012A (zh) | 2018-02-08 | 2021-02-12 | 蜻蜓疗法股份有限公司 | 靶向nkg2d受体的抗体可变结构域 |
WO2019178518A1 (en) * | 2018-03-16 | 2019-09-19 | The Regents Of The University Of California | Cellular signaling domain engineering in chimeric antigen receptor-modified regulatory t cells |
GB201903479D0 (en) * | 2019-03-14 | 2019-05-01 | Univ Oxford Innovation Ltd | Polypeptide with enchanced rate of spontaneous isopeptide bond formation with it's peptide tag partner and uses thereof |
JP2022527351A (ja) * | 2019-04-02 | 2022-06-01 | イーライ リリー アンド カンパニー | 結合ペプチドを選択し検出するための方法 |
CN111848733B (zh) * | 2019-04-30 | 2024-03-12 | 上海细胞治疗集团有限公司 | 一种多肽组合物及疫苗 |
WO2020242988A2 (en) * | 2019-05-24 | 2020-12-03 | Avitide, Inc. | Affinity agents |
WO2020242765A1 (en) * | 2019-05-31 | 2020-12-03 | Rubryc Therapeutics, Inc. | Meso-scale engineered peptides and methods of selecting |
US20230000997A1 (en) | 2019-08-06 | 2023-01-05 | L.E.A.F. Holdings Group Llc | Processes of preparing polyglutamated antifolates and uses of their compositions |
WO2021100585A1 (ja) * | 2019-11-20 | 2021-05-27 | 国立大学法人東海国立大学機構 | キメラ抗原受容体遺伝子改変リンパ球の調製方法 |
WO2021115333A1 (zh) * | 2019-12-10 | 2021-06-17 | 苏州克睿基因生物科技有限公司 | 一种融合蛋白及表达此蛋白的工程化免疫细胞及其应用 |
CN111560391B (zh) * | 2020-05-21 | 2022-02-11 | 北京大学 | 一种蛋白质异质索烃的生物合成方法 |
CN111732635B (zh) * | 2020-06-22 | 2022-03-22 | 中国医学科学院基础医学研究所 | 与cd123蛋白特异性结合的多肽、多肽复合物、共递送系统及其制备方法与应用 |
CN116261567A (zh) * | 2020-07-03 | 2023-06-13 | 纽约市哥伦比亚大学理事会 | 多功能性正交蛋白嵌合体 |
EP4281566A1 (en) * | 2021-01-20 | 2023-11-29 | Coding Bio Limited | Methods for high throughput screening of chimeric antigen receptors |
WO2023086983A1 (en) * | 2021-11-15 | 2023-05-19 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
WO2023159136A2 (en) * | 2022-02-18 | 2023-08-24 | Dana-Farber Cancer Institute, Inc. | Epitope engineering of cell-surface receptors |
WO2023177851A1 (en) * | 2022-03-17 | 2023-09-21 | Singular Immune, Inc | Composition and method of use recombinant fusion protein to generate car-immune cells |
WO2023212602A2 (en) * | 2022-04-27 | 2023-11-02 | Board Of Regents, The University Of Texas System | Cd30 hinge and/or transmembrane domain-based chimeric antigen receptors |
CN115028689B (zh) * | 2022-06-15 | 2023-05-30 | 浙江东方基因生物制品股份有限公司 | 特异性检测hpv6和hpv11的双特异性检测试剂盒 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5723286A (en) | 1990-06-20 | 1998-03-03 | Affymax Technologies N.V. | Peptide library and screening systems |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5733731A (en) | 1991-10-16 | 1998-03-31 | Affymax Technologies N.V. | Peptide library and screening method |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
US5922545A (en) | 1993-10-29 | 1999-07-13 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
US5541087A (en) | 1994-09-14 | 1996-07-30 | Fuji Immunopharmaceuticals Corporation | Expression and export technology of proteins as immunofusins |
AU7378096A (en) | 1995-09-28 | 1997-04-17 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
AU4474497A (en) | 1996-10-08 | 1998-05-05 | U-Bisys B.V. | Methods and means for selecting peptides and proteins having specific affinity for a target |
US7763258B2 (en) | 1997-05-20 | 2010-07-27 | The Trustees Of The University Of Pennsylvania | Virus-like particles (VLPs) comprising heterologous multiple membrane spanning proteins |
DE19802708A1 (de) | 1998-01-24 | 1999-07-29 | Hoechst Marion Roussel De Gmbh | Verwendung von hydroxypyridon-haltigen Puderzubereitungen zur Behandlung von Unterschenkel- und Druckgeschwüren |
ID26964A (id) | 1998-02-19 | 2001-02-22 | Xcyte Therapies Inc | Komposisi dan metode untuk pengaturan pengaktifan limfosit |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
DK2067788T3 (da) | 1999-05-18 | 2015-10-19 | Dyax Corp | Fab-fragmentbiblioteker og fremgangsmåder til anvendelse deraf |
WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
ATE337403T1 (de) | 1999-12-24 | 2006-09-15 | Genentech Inc | Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen |
WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
JP4795619B2 (ja) | 2000-07-31 | 2011-10-19 | バイオレックス・セラピューティクス インコーポレイテッド | ウキクサにおける生物学的に活性なポリペプチド類の発現 |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
ES2402527T3 (es) | 2001-12-27 | 2013-05-06 | Glycofi, Inc. | Procedimientos para obtener estructuras de carbohidrato de tipo mamífero mediante ingeniería genética |
WO2003061570A2 (en) | 2002-01-16 | 2003-07-31 | Zyomyx, Inc. | Engineered binding proteins |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US7314974B2 (en) * | 2002-02-21 | 2008-01-01 | Monsanto Technology, Llc | Expression of microbial proteins in plants for production of plants with improved properties |
KR101070518B1 (ko) | 2002-03-19 | 2011-10-05 | 스티칭 디엔스트 랜드보위쿤디그 온데조에크 | 식물에서의 gntⅲ 발현 |
DE60335000D1 (de) | 2002-09-06 | 2010-12-30 | Isogenica Ltd | In vitro peptid-expressionsbank |
SI1539966T1 (sl) | 2002-09-12 | 2010-10-29 | Greenovation Biotech Gmbh | Postopek za produkcijo proteinov |
CA2549932C (en) | 2002-12-20 | 2013-08-20 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
EP1452868A2 (en) | 2003-02-27 | 2004-09-01 | Pepscan Systems B.V. | Method for selecting a candidate drug compound |
AU2004288157B2 (en) | 2003-09-05 | 2011-03-17 | Oregon Health & Science University | Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells |
EP1737971B1 (en) | 2004-01-20 | 2017-08-16 | Merus N.V. | Mixtures of binding proteins |
EA012464B1 (ru) | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Антитело против cd20 и его применение |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
JP2009503115A (ja) * | 2005-08-03 | 2009-01-29 | アールキュー バイオサイエンス インク | IgA及びIgMを媒介する腎臓症を診断するための方法及び組成物 |
EP4316465A3 (en) | 2006-03-15 | 2024-04-24 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
GB0907251D0 (en) * | 2009-04-28 | 2009-06-10 | Univ Leiden | Coplymers |
US10023657B2 (en) * | 2010-10-01 | 2018-07-17 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
KR102062407B1 (ko) | 2010-12-09 | 2020-01-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
WO2014028776A1 (en) | 2012-08-15 | 2014-02-20 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
AU2013318928A1 (en) * | 2012-09-21 | 2015-04-09 | Kaneka Corporation | Protein ligand for affinity isolation matrix |
US20160031996A1 (en) * | 2013-03-14 | 2016-02-04 | Csl Limited | Anti il-3r alpha agents and uses thereof |
US9840539B2 (en) * | 2013-03-14 | 2017-12-12 | University Of Washington Through Its Center For Commercialization | High affinity digoxigenin binding proteins |
US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
WO2016154621A1 (en) | 2015-03-26 | 2016-09-29 | The California Institute For Biomedical Research | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF |
MX2017012679A (es) | 2015-04-06 | 2018-02-09 | Subdomain Llc | Polipeptidos que contienen dominios de union de novo y usos de los mismos. |
KR20160126340A (ko) | 2015-04-23 | 2016-11-02 | 삼성전자주식회사 | 3중-나선 다발 단백질 및 이의 용도 |
WO2019099440A1 (en) | 2017-11-14 | 2019-05-23 | Arcellx, Inc. | Multifunctional immune cell therapies |
JP7285267B2 (ja) | 2017-11-14 | 2023-06-01 | アーセルクス インコーポレイテッド | Dドメイン含有ポリペプチドおよびその使用 |
-
2016
- 2016-04-04 MX MX2017012679A patent/MX2017012679A/es unknown
- 2016-04-04 EA EA201792226A patent/EA201792226A1/ru unknown
- 2016-04-04 PL PL16777107T patent/PL3280432T3/pl unknown
- 2016-04-04 SG SG10202007987QA patent/SG10202007987QA/en unknown
- 2016-04-04 BR BR112017021308-7A patent/BR112017021308A2/pt active Search and Examination
- 2016-04-04 KR KR1020177031697A patent/KR20180012747A/ko not_active Application Discontinuation
- 2016-04-04 CN CN201680032015.3A patent/CN107921090A/zh active Pending
- 2016-04-04 ES ES16777107T patent/ES2866202T3/es active Active
- 2016-04-04 HU HUE16777107A patent/HUE054435T2/hu unknown
- 2016-04-04 CA CA2981711A patent/CA2981711A1/en active Pending
- 2016-04-04 WO PCT/US2016/025868 patent/WO2016164305A1/en active Application Filing
- 2016-04-04 CN CN202210256708.8A patent/CN115160438A/zh active Pending
- 2016-04-04 DK DK16777109.6T patent/DK3280433T3/da active
- 2016-04-04 CA CA2981616A patent/CA2981616A1/en active Pending
- 2016-04-04 US US15/564,319 patent/US10647775B2/en active Active
- 2016-04-04 RS RS20210529A patent/RS61907B1/sr unknown
- 2016-04-04 US US15/564,325 patent/US10662248B2/en active Active
- 2016-04-04 EP EP21155053.8A patent/EP3903804A1/en active Pending
- 2016-04-04 EP EP16777107.0A patent/EP3280432B8/en active Active
- 2016-04-04 DK DK16777107.0T patent/DK3280432T3/da active
- 2016-04-04 SG SG11201708257UA patent/SG11201708257UA/en unknown
- 2016-04-04 EP EP16777109.6A patent/EP3280433B1/en active Active
- 2016-04-04 ES ES16777109T patent/ES2901273T3/es active Active
- 2016-04-04 JP JP2018503725A patent/JP6871232B2/ja active Active
- 2016-04-04 LT LTEP16777107.0T patent/LT3280432T/lt unknown
- 2016-04-04 JP JP2018503726A patent/JP6873101B2/ja active Active
- 2016-04-04 AU AU2016246426A patent/AU2016246426B2/en active Active
- 2016-04-04 CN CN201680032016.8A patent/CN107708720A/zh active Pending
- 2016-04-04 PT PT167771070T patent/PT3280432T/pt unknown
- 2016-04-04 NZ NZ736022A patent/NZ736022A/en unknown
- 2016-04-04 WO PCT/US2016/025880 patent/WO2016164308A1/en active Application Filing
- 2016-04-04 SI SI201631199T patent/SI3280432T1/sl unknown
- 2016-04-05 US US15/564,430 patent/US20180209983A1/en not_active Abandoned
- 2016-04-05 WO PCT/US2016/026054 patent/WO2016164369A2/en active Application Filing
-
2017
- 2017-10-02 MX MX2021013161A patent/MX2021013161A/es unknown
- 2017-10-06 IL IL254907A patent/IL254907B/en active IP Right Grant
- 2017-10-06 PH PH12017501834A patent/PH12017501834A1/en unknown
- 2017-10-11 ZA ZA2017/06875A patent/ZA201706875B/en unknown
-
2018
- 2018-07-11 HK HK18109015.2A patent/HK1249421A1/zh unknown
- 2018-07-11 HK HK18109016.1A patent/HK1249422A1/zh unknown
-
2020
- 2020-01-24 US US16/751,730 patent/US20200362046A1/en not_active Abandoned
- 2020-03-13 US US16/817,755 patent/US11008397B2/en active Active
- 2020-03-20 US US16/824,809 patent/US20210002381A1/en active Pending
-
2021
- 2021-02-09 AU AU2021200810A patent/AU2021200810B2/en active Active
- 2021-03-29 HR HRP20210498TT patent/HRP20210498T1/hr unknown
- 2021-04-13 US US17/228,817 patent/US20210230288A1/en active Pending
- 2021-04-15 JP JP2021068754A patent/JP7244567B2/ja active Active
- 2021-04-27 IL IL282704A patent/IL282704A/en unknown
- 2021-06-03 CY CY20211100483T patent/CY1124453T1/el unknown
-
2022
- 2022-12-22 US US18/145,169 patent/US20240043550A1/en active Pending
-
2023
- 2023-01-23 JP JP2023007753A patent/JP2023052563A/ja active Pending
- 2023-08-22 AU AU2023219820A patent/AU2023219820A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792226A1 (ru) | Полипептиды, содержащие de novo связывающий домен, и их применение | |
MX2023003125A (es) | Proteinas multiespecificas de union al antigeno. | |
EA202090562A1 (ru) | Связывающие gpcr белки и их синтез | |
EA201790247A1 (ru) | Платформа для очистки биспецифичных антител | |
EA201991383A1 (ru) | Антитела против ctla-4 и способы их применения | |
EA201790307A1 (ru) | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки | |
EA201691811A1 (ru) | Варианты гфпд и способы их применения | |
EA201990321A1 (ru) | Биспецифические антителоподобные связывающие белки, которые специфически связываются с cd3 и cd123 | |
AR105444A1 (es) | Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3) | |
WO2017024317A3 (en) | Methods to induce targeted protein degradation through bifunctional molecules | |
EA201892362A1 (ru) | Агонистические антитела, которые связываются с cd40 человека, и варианты их применения | |
EA201791666A1 (ru) | Антитела к cd3, антитела к cd123 и биспецифические антитела, которые специфически связываются с cd3 и/или cd123 | |
EA201890613A1 (ru) | Полипептиды, связывающие cd3 | |
EA201792442A1 (ru) | Биспецифические агенты, связывающие простатический специфический мембранный антиген (psma), и их применение | |
MA50942A (fr) | Protéines de liaison à l'adn modifiées | |
EA201792080A1 (ru) | Гуманизированные анти-c1s антитела и способы их применения | |
MA41313A (fr) | Anticorps de liaison de la protéine april modifiés | |
PH12019500571A1 (en) | Anti-pd-1 antibodies | |
EA202091198A1 (ru) | Полипептиды, содержащие домен d, и их применение | |
BR112017006598A2 (pt) | anticorpo de repetições antidipeptídeo derivado de ser humano (dprs) | |
CY1120997T1 (el) | Πρωτεϊνες συντηξης uti | |
EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins | |
BR112015019719A2 (pt) | Proteínas melhoradas de ligação ao tnf | |
EA201790725A1 (ru) | Основанные на близости расположения способы выбора партнеров для связывания |